Tags : APD418

Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients

Shots: The US FDA has granted FT designation to APD418, currently in development for the treatment of DHF  The FDA’s Fast Track designation facilitate the development and expedite the review of therapy to treat serious conditions and fill an unmet medical need APD418 is a first-in-class β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, designed to […]Read More